Category Archives: Marketing

Chats Not Charts: Three Steps to Pharma Post-Marketing

by Andrew Spong (originally published on stwem.com) The air of despondency that is descending over the pharmaceutical industry’s use of social media is perverse. It has nothing to do with a putative (and also fictive) absence of interest on the patient’s part in connecting with the pharmaceutical industry. It has everything to do with the […]
Also posted in Advertising, E-Media, Guest Blog, leadership, Patient Communication, patient education, social media, Strategy | Leave a comment

Closed-Loop Marketing: What Comes Next?

By Morten Hjemlsoe. One of the questions I’m increasingly being asked at conferences is, “What’s next after CLM?” That’s actually rather nice to hear. To me, the question is like those delightful birds, the swallows, whose appearance announces that spring is on its way: it signifies that we’re ready for things to change.
Also posted in E-Media, Guest Blog, multimedia, Technology | Tagged , , , , , | Leave a comment

Pharma Marketers: Avoid the Tactical Scrum

by Al Topin With the introduction of every new technology, tactic, or gimmick comes what I call a tactical scrum. It’s like watching young kids play their first game of T-ball or soccer. No matter how much instruction the coach gives on field position or game play, the second that ball is hit or kicked, […]
Also posted in Advertising, Agency Insight, E-Media, Guest Blog, People, Sales, social media, Strategy, Technology | Tagged , , , | Leave a comment

Making the Most of Disruptive Digital Technologies

Peter Houston looks at the pharma marketing takeaways from last week’s Digital Innovation Summit.
Also posted in E-Media, Europe, Events, Global, multimedia, Op-Ed, social media, Technology | Tagged , , , | Leave a comment

FDA, Sponsors Seek Study Endpoints Earlier in Development

As payers demand more evidence documenting medical product value, biopharma companies are responding by moving sooner to decide key clinical outcomes to measure. While clinical trials still have to document product safety, efficacy and quality, sponsors also look to demonstrate suitability for formulary placement and reimbursement. Food and Drug Administration officials support these strategies to […]
Also posted in FDA, R&D, Regulatory, Strategy | Tagged , , , , | 1 Comment
  • Categories

  • Meta